A multi-center, observational, cohort study investigating the efficacy and safety of sofosbuvir and ribavirin in patients with hepatitis C virus in German hepatitis C-registry in real-world setting

Trial Profile

A multi-center, observational, cohort study investigating the efficacy and safety of sofosbuvir and ribavirin in patients with hepatitis C virus in German hepatitis C-registry in real-world setting

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Sofosbuvir (Primary) ; Daclatasvir; Ledipasvir/sofosbuvir; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2016 New trial record
    • 17 Apr 2016 Results of patients with HCV genotype 2 infection (n=194) presented at The International Liver Congress™ 2016
    • 17 Apr 2016 Subgroup analysis (n=706) of SVR rates of ledipasvir/sofosbuvir treatment for 8-12 weeks until September 2015, in hepatitis C genotype 1 treatment-naive patients were presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top